Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe 11:20:00 2024-04-24 am EDT 5-day change 1st Jan Change
222.2 CHF -3.27% Intraday chart for Roche Holding AG +1.00% -9.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Roche Holding AG, Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024
ROCHE HOLDINGS AG : Barclays remains Neutral ZD
ROCHE HOLDINGS AG : UBS reaffirms its Neutral rating ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump RE
Roche Eyes Potential M&A Deals Amid Pipeline Restructure MT
Shares jump on tech boost; fragile yen on intervention watch RE
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating ZD
Roche Sees Return to Growth Ahead After Forex, Post-pandemic Slump Hit First-quarter Sales MT
ROCHE HOLDINGS AG : Jefferies reaffirms its Neutral rating ZD
Roche: 2% growth in sales at constant exchange rates in Q1 CF
ROCHE HOLDINGS AG : Buy rating from Bernstein ZD
European shares flat, with focus on mixed bag of earnings RE
Correction to Roche Article DJ
Roche Sales Decline on Currency Hit DJ
Swiss Drugmaker Roche's Q1 Sales Fall; FY24 Outlook Confirmed MT
Roche Q1 sales down 6% on forex effect, loss of COVID revenue RE
Roche Holding AG Reports Sales Results for the First Quarter Ended March 2024 CI
Roche Holding AG Provides Earnings Guidance for the Year 2024 CI
EMEA Morning Briefing: Shares May Rise as Investors Brace for Earnings DJ
Swiss Equities Flash Green; Middle East Tensions Rise MT
Roche: approval in lung cancer in the United States CF
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine MT
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval DJ
Roche's Early-stage Lung Cancer Treatment Alecensa Wins US FDA Nod MT
FDA Approves Roche?s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer CI
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
229.7 CHF
Average target price
281.1 CHF
Spread / Average Target
+22.36%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Develops New COVID-19 PCR Test for Omicron Subvariant XBB.1.5